Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with chemotherapy plus trastuzumab and lapatinib as neoadjuvant therapy for HER2-positive breast cancer
PubMed Full text in PMC Similar studies Analyze with GEO2R
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
[GenomeWideSNP_6] Affymetrix Genome-Wide Human SNP 6.0 Array
sample_99_11-RG-005 [expression]
sample_98_11-IS-004 [expression]
sample_97_11-EV-003 [expression]
sample_96_11-EB-002 [expression]
sample_95_05-CB-005 [expression]
sample_94_08-FR-07 [expression]
sample_93_08-CM-05 [expression]
sample_91_08-KA-04 [expression]
sample_90_08-ZMT-06 [expression]
sample_88_03-CV-002 [expression]
sample_87_01-PD-016 [expression]
sample_84_05-LR-004 [expression]
sample_83_05-LA-003 [expression]
sample_82_05-LF-002 [expression]
sample_79_01-AG-015 [expression]
sample_78_07-MS-003 [expression]
sample_77_07-SF-002 [expression]
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on